TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38039427
Drug: Canakinumab plus
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab plus pembrolizumab and chemotherapy
Study: 38039427
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus pembrolizumab and chemotherapy
Study: 38039991
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg intravenously once every 4 weeks) with chemoradiotherapy
Study: 38040478
Drug: Daily or
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily or event-based oral PrEP (tenofovir disoproxil maleate with emtricitabine)
Study: 38040541
Drug: Daily cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cup of study beans added to usual diet
Study: 38040875
Drug: Antenatal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroid therapy (ACS)
Study: 38041148
Drug: online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: online cognitive behavioural therapy intervention based on the unified protocol
Study: 38041177
Drug: Hyponatremia (natremia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyponatremia (natremia <135 mmol/L)
Study: 38041177
Drug: Normal natremia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal natremia (135-145 mmol/L)
Study: 38041177
Drug: Hypernatremia (natremia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypernatremia (natremia >145 mmol/L)
Study: 38042412
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g GOS/FOS + iron
Study: 38042412
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g GOS/FOS + iron
Study: 38042525
Drug: Osimertinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib plus platinum-pemetrexed (combination)
Study: 38042773
Drug: Robot for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot for medication management
Study: 38042801
Drug: BUP-XR 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR 300-mg maintenance dose
Study: 38042801
Drug: BUP-XR 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR 100-mg maintenance dose
Study: 38042801
Drug: BUP-XR 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR 100-mg and 300-mg maintenance doses
Study: 38042811
Drug: Daily respiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily respiratory exercises
Study: 38042851
Drug: Olipudase alfa
Normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olipudase alfa treatment for 2 years
Study: 38042851
Drug: Cross-over group
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over group after 1 year of olipudase alfa treatment
Study: 38043867
Drug: Daytime home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daytime home parenteral nutrition (HPN)
Study: 38043867
Drug: Overnight home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight home parenteral nutrition (HPN)
Study: 38043911
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg, twice daily)
Study: 38044460
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Tranexamic acid (TXA)
Study: 38044460
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Tranexamic acid (TXA)
Study: 38045803
Drug: Monthly BUP-XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly BUP-XR (Sublocade;® two injections of 300 mg, then four maintenance injections of 100 mg or 300 mg) for 24 weeks
Study: 38045803
Drug: Daily standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily standard-of-care (SoC) medication (liquid methadone 60-120 mg or sublingual/transmucosal buprenorphine 8-24 mg) for 24 weeks
Study: 38045803
Drug: BUP-XR among
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR among participants in maintenance treatment for more than 28 days
Study: 38046839
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal catheter therapy
Study: 38046981
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 400 µg administered via dry powder inhaler, single and multiple (twice daily) doses.
Study: 38047142
Drug: Methadone (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.10 mg/kg to 0.20 mg/kg)
Study: 38047249
Drug: SNG100 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNG100 cream (hydrocortisone 1% in a cream base with sulphated polysaccharide), applied twice daily for 14 days
Study: 38047249
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% cream, applied once daily for 14 days
Study: 38047249
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% cream, applied twice daily for 14 days
Study: 38047249
Drug: SNG100 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNG100 cream
Study: 38048045
Drug: 177Lu-DOTATATE at
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-DOTATATE at a dose of 7.4 GBq (200 mCi) every eight weeks for four cycles
Study: 38048133
Drug: Thiazide-type diuretic
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-type diuretic
Study: 38048134
Drug: Cilostazol, 50
Normalized name: Cilostazol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol, 50 mg twice daily for up to 96 weeks
Study: 38048134
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 tablet twice daily for up to 96 weeks
Study: 38048188
Drug: Intravenous levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levothyroxine (30 μg per hour for a minimum of 12 hours)
Study: 38048188
Drug: Intravenous levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levothyroxine
Study: 38048786
Drug: Imetelstat 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat 7.5 mg/kg administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Study: 38048786
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Study: 38048793
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus standard therapy (cisplatin 50 mg/m2)
Study: 38048793
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (cisplatin 50 mg/m2)
Study: 38048799
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (oral dose of 14,000 IU/week)
Study: 38048802
Drug: Neoadjuvant chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemo-immunotherapy with camrelizumab (one cycle of priming doublet chemotherapy at 75-80 mg/m2)
Study: 38048802
Drug: Neoadjuvant chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemo-immunotherapy with camrelizumab
Study: 38049197
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam (BRV) 0.5 mg/kg intravenously (IV) twice daily (b.i.d)
Study: 38049523
Drug: Intracranial injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracranial injection of poly(I:C)
Study: 38049783
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (CRT)
Study: 38049955
Drug: EDV add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDV add-on treatment to TAU (intravenous infusion with 30 mg of EDV twice per day)
Study: 38049955
Drug: NGF add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF add-on treatment to TAU (intramuscular injection of 20 μg of NGF per day)
Study: 38049955
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU: a combination of intramuscular injections of thiamine, intravenous infusions of other B vitamins with vitamin C and oral medication with vitamin E per day)
Study: 38049955
Drug: EDV add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDV add-on treatment to TAU
Study: 38050737
Drug: CA19-9-normal subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA19-9-normal subgroup (≤37 U/mL)
Study: 38050737
Drug: CA19-9-high subgroup
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA19-9-high subgroup (>37 U/mL)
Study: 38051008
Drug: EnhanceFitness (EF)
Normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EnhanceFitness (EF) physical activity intervention, 12-week duration, thrice weekly classes
Study: 38051292
Drug: Not using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not using hormone therapy
Study: 38051328
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Study: 38051328
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Study: 38051699
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Study: 38051699
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Study: 38051700
Drug: Enhanced vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced vitamin supplement
Study: 38051700
Drug: Standard vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vitamin supplement (control)
Study: 38051723
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT) combined with exercise (balance, strengthening, and mobility exercises guided by 15-minute action observation videos before a 45-minute exercise session)
Study: 38051750
Drug: Peposertib 50-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peposertib 50-250 mg once daily plus capecitabine 825 mg/m2 twice daily and radiotherapy 5 days per week
Study: 38051750
Drug: Peposertib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peposertib 100 mg cohort
Study: 38051750
Drug: Peposertib ≤150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peposertib ≤150 mg once daily
Study: 38052042
Drug: Teclistamab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab 1.5 mg/kg subcutaneously once weekly
Study: 38052302
Drug: Protein-rich oral
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich oral nutritional supplement for 4 weeks before TAVR with home-based supervised exercise sessions for 12 weeks after TAVR
Study: 38052851
Drug: PEDF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEDF treatment of human skin fibroblast (HSF) cell lines with different concentrations and durations.
Study: 38053101
Drug: Attitudes toward
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Attitudes toward drugs measured by the Drug Attitude Inventory (DAI-10) at baseline
Study: 38053122
Drug: Group Brief
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Brief Cognitive Behavioral Therapy (G-BCBT)
Study: 38053122
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) Skills Group
Study: 38053197
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy
Study: 38053196
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholic acid (TUDCA) as add-on therapy to riluzole
Study: 38053515
Drug: Once-daily somatropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily somatropin
Study: 38053657
Drug: H-IGRT (hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-IGRT (hypofractionated 15 fractions/3 weeks image-guided radiation therapy)
Study: 38053657
Drug: CRT (normofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT (normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy)
Study: 38053659
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy (25-40 Gy/5 Fx for cohort A; 15-30 Gy/5 Fx for cohort B), chemotherapy, toripalimab, and stereotactic ablative radiotherapy (SABR) for all metastatic lesions.
Study: 38054696
Drug: JX11502MA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 0.25 mg
Study: 38054696
Drug: JX11502MA 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 0.5 mg
Study: 38054696
Drug: JX11502MA 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 1 mg
Study: 38054696
Drug: JX11502MA 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 2 mg
Study: 38054696
Drug: JX11502MA 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 3 mg
Study: 38054696
Drug: JX11502MA 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 6 mg
Study: 38054696
Drug: JX11502MA 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: JX11502MA 8 mg
Study: 38055176
Drug: Dual-pathway inhibition
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-pathway inhibition (DPI) with rivaroxaban and low-dose aspirin
Study: 38055186
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil after clinical worsening
Study: 38055186
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by oral treprostinil after clinical worsening
Study: 38055237
Drug: Telemonitoring strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring strategy (4 daily SMS messages)
Study: 38055242
Drug: RGRN-305, 250-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGRN-305, 250-mg tablet, once daily for 16 weeks
Study: 38055242
Drug: Placebo, matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matching tablet, once daily for 16 weeks
Study: 38055253
Drug: Mirvetuximab soravtansine
Normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvetuximab soravtansine (MIRV) 6 mg/kg every 3 weeks
Study: 38055253
Drug: Chemotherapy (paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan)
Study: 38055353
Drug: MR-guided stereotactic
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided stereotactic body radiation therapy (SBRT) with 40 Gy prescribed to 95% of the PTV in over five fractions
Study: 38056770
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support tool for managing oral anticoagulation (visualized in intervention centers)
Study: 38056900
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) combined with adenosine pathway inhibitor oleclumab and neo-adjuvant immuno-chemotherapy (paclitaxel, doxorubicin/cyclophosphamide, durvalumab)
Study: 38057377
Drug: BIS group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS group (10 mg/kg/h propofol infusion adjusted to keep the BIS value between 40 and 60)
Study: 38057377
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (0.5 mg/kg of propofol when necessary)
Study: 38057636
Drug: Cipaglucosidase alfa
Normalized name: Cipaglucosidase alfa
DrugBank: Cipaglucosidase alfa (DB16708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipaglucosidase alfa plus miglustat (20 mg/kg intravenous-infused cipa plus 260 mg oral mig biweekly)
Study: 38057695
Drug: Epidural nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural nalbuphine (2 ml, 10 mg)
Study: 38057695
Drug: Epidural dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural dexmedetomidine (2 ml, 100 µg)
Study: 38057695
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (10 ml 0.25% + 2 ml normal saline)
Study: 38057772
Drug: LXI-15029, 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: LXI-15029, 110 mg BID (maximum tolerated dose)
Study: 38057844
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg tablet) with iftar meal during Ramadan
Study: 38057875
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole intravenously
Study: 38057919
Drug: HepB3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HepB3 vaccine
Study: 38058646
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy program using elastic bands (16 sessions, 45 minutes each)
Study: 38058795
Drug: Semaglutide 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.1, 0.2, or 0.4 mg
Study: 38059202
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) at gallbladder meridian acupoint (GBA)
Study: 38059202
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) at non-acupoint (NA)
Study: 38059497
Drug: Arfolitixorin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2)
Study: 38059497
Drug: Leucovorin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (400 mg/m2 given as a single intravenous infusion)
Study: 38059635
Drug: Oral ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ceftibuten
Study: 38059946
Drug: 0.60 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.60 g/kg alcohol during late follicular phase (E2 elevated)
Study: 38060092
Drug: Fast-eluting implant
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-eluting implant (n = 51)
Study: 38060092
Drug: Slow-eluting implant
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-eluting implant (n = 54)
Study: 38060195
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of radiotherapy with endocrine therapy for 5 years
Study: 38060199
Drug: Triplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet therapy (atezolizumab 840 mg, ipatasertib 400 mg/day, paclitaxel 80 mg/m2 or nab-paclitaxel 100 mg/m2)
Study: 38060199
Drug: Triplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet therapy
Study: 38060545
Drug: Psychoeducational video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational video prescriptions about BPD
Study: 38060545
Drug: Psychoeducational video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational video prescriptions about non-BPD mental health topics
Study: 38060549
Drug: Placebo medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medicine
Study: 38060997
Drug: Transcatheter edge-to-edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter edge-to-edge repair (TEER) with the MitraClip™ device plus guideline-directed medical therapy (GDMT)
Study: 38061271
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg ARA and 50 mg/kg DHA (ARA:DHA group)
Study: 38061367
Drug: VAX-24 (1·1
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens)
Study: 38061367
Drug: VAX-24 (2·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX-24 (2·2 μg)
Study: 38061370
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg once per day
Study: 38061376
Drug: Three-drug nevirapine-based
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-drug nevirapine-based ART (cohort 1)
Study: 38061376
Drug: Three-drug nevirapine-based
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-drug nevirapine-based prophylaxis followed by three-drug nevirapine-based ART (cohort 2)
Study: 38061553
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy and ST
Study: 38062157
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for obesity for 8 weeks
Study: 38062475
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 10 weeks focusing on anxiety
Study: 38064219
Drug: Trauma Center
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Center Trauma-Sensitive Yoga (TCTSY) - 10 weekly, 60-minute group sessions
Study: 38064219
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) - 12 weekly, 90-minute group sessions
Study: 38064260
Drug: S(+)-ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)-ketamine (0.3 mg/kg/h)
Study: 38064262
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily steps (measured using Fitbit-HR Charge 2)